In December 2024, a 27-year-old woman initiated a self-experimentation protocol within the confines of her childhood bedroom in a Boston suburb. Identified as Rebecca, who prefers to be called Becks, she embarked on this endeavor as a deeply personal and unconventional attempt to address a decade-long struggle with substance addiction.
Her method involved the self-administration of an unapproved synthetic compound known as SR-17018. At 4:27 a.m. on a chosen morning, Becks prepared and ingested a precisely measured 25-milligram dose of the substance. The compound, supplied in a plastic bag stamped with a clear warning, “NOT FOR HUMAN CONSUMPTION,” was a white powder that she carefully weighed on a digital scale before encapsulating it for ingestion.
Becks documented her experience in an online diary, noting, “It’s my turn to be a guinea pig.” She chose to share her narrative with The New York Times, requesting anonymity regarding her full name to mitigate potential repercussions on future employment opportunities due to her history of drug use.
This private undertaking places Becks among a growing, albeit dangerous and highly speculative, contingent of individuals adopting a do-it-yourself approach to addiction recovery. Her addiction history encompassed various substances, most recently kratom, an opiate-like botanical known for its pain-relieving and mood-altering properties, which necessitated frequent dosing to mitigate withdrawal symptoms. She also reported past experiences with fentanyl, a potent synthetic opioid, underscoring the severity of her addiction challenges.
Becks described her life while dependent on kratom as a “grim existence,” characterized by nocturnal withdrawals that left her “drenched in sweat every morning.” Her efforts to achieve sobriety through conventional means had been extensive but ultimately unsustainable. These included three brief inpatient detoxifications and a month-long rehabilitation program. Despite periods of abstinence, she had been unable to maintain long-term recovery, leading to a profound sense of desperation.
It was in this context that she learned about SR-17018. This substance is one of numerous novel psychoactive substances (NPS) that are synthetically produced, primarily in manufacturing hubs such as China, and distributed globally through online channels. These compounds are typically unregulated, have not undergone rigorous safety or efficacy testing for human use, and are often associated with significant, potentially lethal, health risks. Despite these dangers, their accessibility online makes them attractive to individuals seeking unconventional solutions.
While the majority of NPS are engineered to induce psychoactive effects and are consumed recreationally, SR-17018 presents a unique deviation. It has gained attention within certain communities, particularly online forums like Reddit, for its purported utility in mitigating drug dependence. This perception stems largely from a 2019 study, which suggested that SR-17018 could alleviate drug addiction in laboratory mice.
The dissemination of this animal study’s findings through online platforms, rather than through established medical and scientific channels for human trials, has fueled speculative use among individuals struggling with addiction. This phenomenon highlights a critical intersection of unmet medical needs, the global proliferation of unregulated synthetic drugs, and the rapid, often unchecked, spread of information and anecdotal claims through digital communities.
The decision by individuals like Becks to self-administer such compounds underscores a complex public health challenge. The inherent dangers are multifold: the substances lack quality control, meaning their purity and actual composition can vary wildly; dosages are not standardized for human physiology, leading to unpredictable effects; and there is a complete absence of data regarding potential short-term and long-term side effects, drug interactions, or toxicology in humans. Regulatory agencies globally struggle to keep pace with the emergence of these new chemicals, which are often modified slightly to bypass existing drug laws.
Becks’ narrative is a poignant example of the extreme measures individuals are willing to take in the relentless pursuit of sobriety when conventional treatments have proven insufficient or inaccessible. Her story reflects a broader trend of individuals navigating the frontiers of self-experimentation, driven by desperation and the seductive promise of an unregulated “cure” found outside the established medical framework. The lack of clinical research and regulatory oversight for SR-17018 in humans means that anyone using it is effectively engaging in an uncontrolled experiment with their own health and life at stake, without the ethical protections, scientific rigor, or medical supervision inherent in legitimate clinical trials. This burgeoning underground movement for addiction treatment, based on preliminary animal studies and anecdotal reports, represents a concerning development in the ongoing global struggle against substance use disorders.
The global scale of the opioid crisis and other drug dependencies has spurred an urgent demand for novel and more effective treatments. However, the path to approved medications is long, expensive, and fraught with scientific challenges. The vacuum created by this unmet need, coupled with the rapid evolution of online drug markets, encourages vulnerable individuals to explore perilous alternatives, transforming their homes into makeshift laboratories in a desperate bid for recovery.
Why This Matters
This situation highlights several critical global issues at the intersection of public health, drug regulation, and individual desperation. First, it underscores the profound and widespread impact of substance use disorders, demonstrating the lengths to which individuals will go in search of effective treatment when traditional methods have failed or are inaccessible. This desperation can drive vulnerable populations to engage in highly risky behaviors, including self-experimentation with unapproved and potentially lethal substances.
Second, the emergence of novel psychoactive substances (NPS) like SR-17018, manufactured primarily in places like China and distributed globally online, represents a significant challenge for international drug control and public health agencies. These substances evade existing regulations due to their constantly evolving chemical structures, making it difficult to monitor, control, and inform the public about their dangers. The “NOT FOR HUMAN CONSUMPTION” label on such products often serves as a legal disclaimer rather than a genuine impediment to their illicit use.
Third, the role of online platforms, particularly social media and forums like Reddit, in disseminating unverified scientific claims and encouraging dangerous self-treatment practices is a growing concern. A single animal study, far from human clinical validation, can be amplified and misinterpreted, leading individuals to undertake life-threatening experiments based on incomplete or misleading information. This phenomenon underscores the need for greater digital literacy and more robust fact-checking mechanisms regarding health information online.
Finally, this scenario emphasizes the urgent global demand for safe, effective, and accessible addiction treatments. The slow pace of drug development and regulatory approval for new medications for substance use disorders creates a void that is often filled by the black market and dangerous do-it-yourself approaches. Addressing this requires sustained investment in addiction research, streamlined regulatory processes for promising treatments, and expanded access to evidence-based care to prevent individuals from resorting to such perilous methods in their quest for sobriety.